|
Not rare. Well, let's see..... HER2+ is about 25-30% of all bc? About half of HER2+ bc is ERPR+, which is a little lower ratio to ERPR- than in non HER2+ bc, so perhaps the oncologist meant that it's a little less likely to ERPR+ than with HER2- bc? But still hardly rare. Math is not my strong point. Do you figure that to be about 12.5 to 15% of all bc being HER2+, ERPR+?
By the time you break all bc down just by HER2 and hormonal status (not to mention the many other details of pathology), most individual categories are probably not a lot bigger than 15%. I guess HER2-/ERPR+ is the most common - about half of all? Like I said, please check my math.
Debbie L.
|